Cargando…

What should be the protocol selection after failure of in-vitro fertilization at normoresponder patients: Agonist or antagonist?

OBJECTIVE: Evaluation of the impact of agonist or antagonist protocol selection on pregnancy outcomes after failure of in-vitro fertilization (IVF) treatment cycles which were down regulated with Gonadotropin Releasing Hormone (GnRH) agonist. MATERIALS AND METHODS: This was a retrospective study. Tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceyhan, Seyit Temel, Bayoğlu Tekin, Yeşim, Sakinci, Mehmet, Ercan, Cihangir Mutlu, Keskin, Uğur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558360/
https://www.ncbi.nlm.nih.gov/pubmed/28913019
http://dx.doi.org/10.4274/tjod.03789
_version_ 1783257377431093248
author Ceyhan, Seyit Temel
Bayoğlu Tekin, Yeşim
Sakinci, Mehmet
Ercan, Cihangir Mutlu
Keskin, Uğur
author_facet Ceyhan, Seyit Temel
Bayoğlu Tekin, Yeşim
Sakinci, Mehmet
Ercan, Cihangir Mutlu
Keskin, Uğur
author_sort Ceyhan, Seyit Temel
collection PubMed
description OBJECTIVE: Evaluation of the impact of agonist or antagonist protocol selection on pregnancy outcomes after failure of in-vitro fertilization (IVF) treatment cycles which were down regulated with Gonadotropin Releasing Hormone (GnRH) agonist. MATERIALS AND METHODS: This was a retrospective study. Two hundred and sixty nine patients who were treated with GnRH agonist protocol between years 2002-2012 at an IVF unit and underwent a second attempt following one year period after failure of IVF enrolled in the study. Age, basal FSH levels, antral follicle counts, duration of induction, the number of yielded oocytes, the number of transferred embryos and the transfer days, clinical and ongoing pregnancy rates were evaluated for each treatment cycle. RESULTS: Normoresponder patients were separated into two groups according to the agonist or antagonist protocol selection at the second attempt and the results of two consequent IVF cycles were compared. There were no statistically significant difference between the groups for the dosage of administered gonadotropin, duration of induction, the count of yielded oocytes, the day and the number of transferred embryos (p>0.05). Furthermore the fertilization rate, clinical and ongoing pregnancy rates were similar in two groups. CONCLUSION: The selection of antagonist treatment is effective as agonist protocols at normoresponder patients after failure of IVF.
format Online
Article
Text
id pubmed-5558360
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-55583602017-09-14 What should be the protocol selection after failure of in-vitro fertilization at normoresponder patients: Agonist or antagonist? Ceyhan, Seyit Temel Bayoğlu Tekin, Yeşim Sakinci, Mehmet Ercan, Cihangir Mutlu Keskin, Uğur Turk J Obstet Gynecol Clinical Investigation OBJECTIVE: Evaluation of the impact of agonist or antagonist protocol selection on pregnancy outcomes after failure of in-vitro fertilization (IVF) treatment cycles which were down regulated with Gonadotropin Releasing Hormone (GnRH) agonist. MATERIALS AND METHODS: This was a retrospective study. Two hundred and sixty nine patients who were treated with GnRH agonist protocol between years 2002-2012 at an IVF unit and underwent a second attempt following one year period after failure of IVF enrolled in the study. Age, basal FSH levels, antral follicle counts, duration of induction, the number of yielded oocytes, the number of transferred embryos and the transfer days, clinical and ongoing pregnancy rates were evaluated for each treatment cycle. RESULTS: Normoresponder patients were separated into two groups according to the agonist or antagonist protocol selection at the second attempt and the results of two consequent IVF cycles were compared. There were no statistically significant difference between the groups for the dosage of administered gonadotropin, duration of induction, the count of yielded oocytes, the day and the number of transferred embryos (p>0.05). Furthermore the fertilization rate, clinical and ongoing pregnancy rates were similar in two groups. CONCLUSION: The selection of antagonist treatment is effective as agonist protocols at normoresponder patients after failure of IVF. Galenos Publishing 2014-12 2014-12-15 /pmc/articles/PMC5558360/ /pubmed/28913019 http://dx.doi.org/10.4274/tjod.03789 Text en © Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Investigation
Ceyhan, Seyit Temel
Bayoğlu Tekin, Yeşim
Sakinci, Mehmet
Ercan, Cihangir Mutlu
Keskin, Uğur
What should be the protocol selection after failure of in-vitro fertilization at normoresponder patients: Agonist or antagonist?
title What should be the protocol selection after failure of in-vitro fertilization at normoresponder patients: Agonist or antagonist?
title_full What should be the protocol selection after failure of in-vitro fertilization at normoresponder patients: Agonist or antagonist?
title_fullStr What should be the protocol selection after failure of in-vitro fertilization at normoresponder patients: Agonist or antagonist?
title_full_unstemmed What should be the protocol selection after failure of in-vitro fertilization at normoresponder patients: Agonist or antagonist?
title_short What should be the protocol selection after failure of in-vitro fertilization at normoresponder patients: Agonist or antagonist?
title_sort what should be the protocol selection after failure of in-vitro fertilization at normoresponder patients: agonist or antagonist?
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558360/
https://www.ncbi.nlm.nih.gov/pubmed/28913019
http://dx.doi.org/10.4274/tjod.03789
work_keys_str_mv AT ceyhanseyittemel whatshouldbetheprotocolselectionafterfailureofinvitrofertilizationatnormoresponderpatientsagonistorantagonist
AT bayoglutekinyesim whatshouldbetheprotocolselectionafterfailureofinvitrofertilizationatnormoresponderpatientsagonistorantagonist
AT sakincimehmet whatshouldbetheprotocolselectionafterfailureofinvitrofertilizationatnormoresponderpatientsagonistorantagonist
AT ercancihangirmutlu whatshouldbetheprotocolselectionafterfailureofinvitrofertilizationatnormoresponderpatientsagonistorantagonist
AT keskinugur whatshouldbetheprotocolselectionafterfailureofinvitrofertilizationatnormoresponderpatientsagonistorantagonist